IGF2BP3 and lung adenocarcinoma: By “oncoppredict”, BI-2536 has potential therapeutic value for patients with low IGF2BP3 expression, which provides a reference for precise clinical treatment—not only as a prognostic biomarker and immunotherapy predictor, but also as a potential therapeutic target in lung adenocarcinoma treatment.